MOA Life Plus (A142760) Stock Overview
Engages in the medicine and consumer business in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A142760 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
MOA Life Plus Co. Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩805.00 |
| 52 Week High | ₩2,250.00 |
| 52 Week Low | ₩785.00 |
| Beta | 1.28 |
| 1 Month Change | -54.13% |
| 3 Month Change | -52.81% |
| 1 Year Change | -38.08% |
| 3 Year Change | -81.15% |
| 5 Year Change | -84.81% |
| Change since IPO | -94.33% |
Recent News & Updates
Is MOA Life Plus (KOSDAQ:142760) Using Debt In A Risky Way?
Jan 22
Is MOA Life Plus (KOSDAQ:142760) Using Too Much Debt?
Oct 01MOA Life Plus Co. Ltd.'s (KOSDAQ:142760) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jun 10Recent updates
Is MOA Life Plus (KOSDAQ:142760) Using Debt In A Risky Way?
Jan 22Is MOA Life Plus (KOSDAQ:142760) Using Too Much Debt?
Oct 01MOA Life Plus Co. Ltd.'s (KOSDAQ:142760) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jun 10Health Check: How Prudently Does MOA Life Plus (KOSDAQ:142760) Use Debt?
Feb 06Health Check: How Prudently Does MOA Life Plus (KOSDAQ:142760) Use Debt?
Oct 18There's No Escaping Bioleaders Corporation's (KOSDAQ:142760) Muted Revenues Despite A 30% Share Price Rise
Apr 19Bioleaders Corporation's (KOSDAQ:142760) Business And Shares Still Trailing The Industry
Mar 01Bioleaders' (KOSDAQ:142760) Shareholders Are Down 47% On Their Shares
Feb 16
Shareholder Returns
| A142760 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -25.5% | 1.9% | 5.3% |
| 1Y | -38.1% | 48.1% | 109.3% |
Return vs Industry: A142760 underperformed the KR Biotechs industry which returned 48.1% over the past year.
Return vs Market: A142760 underperformed the KR Market which returned 109.3% over the past year.
Price Volatility
| A142760 volatility | |
|---|---|
| A142760 Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 13.2% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A142760's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A142760's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 41 | n/a | www.moalifeplus.com |
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug.
MOA Life Plus Co. Ltd. Fundamentals Summary
| A142760 fundamental statistics | |
|---|---|
| Market cap | ₩32.89b |
| Earnings (TTM) | -₩11.93b |
| Revenue (TTM) | ₩9.80b |
Is A142760 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A142760 income statement (TTM) | |
|---|---|
| Revenue | ₩9.80b |
| Cost of Revenue | ₩7.45b |
| Gross Profit | ₩2.35b |
| Other Expenses | ₩14.28b |
| Earnings | -₩11.93b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -292.32 |
| Gross Margin | 24.00% |
| Net Profit Margin | -121.73% |
| Debt/Equity Ratio | 29.8% |
How did A142760 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/23 15:53 |
| End of Day Share Price | 2026/02/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MOA Life Plus Co. Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.